Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12960119 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL9926385 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL1066955 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL12960118 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL12374824 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL5945027 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL23348053 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL12230286 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL13182827 | 1.00 | THRB (0.37) | THRBLMNA | |
| SCHEMBL12498624 | 1.00 | THRB (0.37) | THRBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541607-B2 | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof | LACER, S.A. (ES) | 2013-09-24 | — | — | US | disclosed |
| US-7777058-B2 | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof | LACER S.A. (ES) | 2010-08-17 | — | — | US | disclosed |
| US-20100196387-A1 | Disulfide, Sulfide, Sulfoxide, and Sulfone Derivatives of Cyclic Sugars and Uses Thereof | LACER, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20090169560-A1 | DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF | LACER S.A. (ES) | 2009-07-02 | — | — | US | disclosed |
| US-7521571-B2 | Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses | LACER (ES) | 2009-04-21 | — | — | US | disclosed |
| US-20080161389-A1 | METHOD OF TREATING OCULAR HYPERTENSION AND INTESTINAL DISORDERS BY USING DIANHYDROHEXITE MONONITRATE DERIVATIVES | LACER, S.A. (ES) | 2008-07-03 | — | — | US | disclosed |
| WO-2007120458-A1 | LIQUID CRYSTAL COMPOSITIONS, POLYMER NETWORKS DERIVED THEREFROM AND PROCESS FOR MAKING THE SAME | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2007-10-25 | — | — | WO | disclosed |
| US-20070152188-A1 | Composition for reducing the transmission of infrared radiation | DOW GLOBAL TECHNOLOGIES LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070116945-A1 | High strength multilayer laminates comprising twisted nematic liquid crystals | DOW GLOBAL TECHNOLOGIES LLC | 2007-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090169560-A1 | DISULFIDE, SULFIDE, SULFOXIDE, AND SULFONE DERIVATIVES OF CYCLIC SUGARS AND USES THEREOF | TST, STS, SORD | THRB 1552/4885LMNA 4821/4885 |
| US-20080161389-A1 | METHOD OF TREATING OCULAR HYPERTENSION AND INTESTINAL DISORDERS BY USING DIANHYDROHEXITE MONONITRATE DERIVATIVES | SI, SLC10A2, ALPI | THRB 1930/4885LMNA 2277/4885 |
| US-20100196387-A1 | Disulfide, Sulfide, Sulfoxide, and Sulfone Derivatives of Cyclic Sugars and Uses Thereof | TST, STS, SORD | THRB 1552/4885LMNA 4821/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.